Sutro Biopharma, Inc. Common Stock (STRO) Stock
Fundamentals
Latest news
About Sutro Biopharma, Inc. Common Stock
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Jane Chung R.Ph. | CEO & Director | 1971 |
| Mr. Gregory K. Chow BA, CPA, MBA | Chief Financial Officer | 1973 |
| Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer | 1964 |
| Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder | — |
| Mr. Devendra Luhar | Senior Vice President of Technical Operations | — |
| Mr. David Pauling J.D., M.A. | Chief Administrative Officer & General Counsel | 1974 |
| Ms. Kari E. Leetch | Senior VP and Head of People & Culture | — |
| Mr. Jonathan Fawcett DPHIL, MBBS | VP & Head of Clinical Development | — |
| Ms. Regina Cheng | Vice President & Controller | — |



